guest ::
| Home > Publications database > Identifying metabolic features of colorectal cancer liability using Mendelian randomization. > print |
| Home > Publications database > Identifying metabolic features of colorectal cancer liability using Mendelian randomization. > print |
| 001 | 286383 | ||
| 005 | 20240229155125.0 | ||
| 024 | 7 | _ | |a 10.7554/eLife.87894 |2 doi |
| 024 | 7 | _ | |a pmid:38127078 |2 pmid |
| 024 | 7 | _ | |a altmetric:153220010 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-02786 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 600 |
| 100 | 1 | _ | |a Bull, Caroline |0 0000-0002-2176-5120 |b 0 |
| 245 | _ | _ | |a Identifying metabolic features of colorectal cancer liability using Mendelian randomization. |
| 260 | _ | _ | |a Cambridge |c 2023 |b eLife Sciences Publications |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1703245028_28909 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival.To investigate whether changes in circulating metabolites characterize the early stages of colorectal cancer (CRC) development, we examined the associations between a genetic risk score (GRS) associated with CRC liability (72 single-nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N = 6221). Linear regression models were applied to examine the associations between genetic liability to CRC and circulating metabolites measured in the same individuals at age 8 y, 16 y, 18 y, and 25 y.The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P < 0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N = 118,466, median age 58 y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk.These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism and suggest that fatty acids may play an important role in CRC development.This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Mendelian randomization |2 Other |
| 650 | _ | 7 | |a cancer biology |2 Other |
| 650 | _ | 7 | |a colorectal cancer |2 Other |
| 650 | _ | 7 | |a epidemiology |2 Other |
| 650 | _ | 7 | |a global health |2 Other |
| 650 | _ | 7 | |a human |2 Other |
| 650 | _ | 7 | |a metabolomics |2 Other |
| 650 | _ | 7 | |a obesity |2 Other |
| 700 | 1 | _ | |a Hazelwood, Emma |0 0000-0002-4888-6037 |b 1 |
| 700 | 1 | _ | |a Bell, Joshua A |b 2 |
| 700 | 1 | _ | |a Tan, Vanessa |0 0000-0001-7938-127X |b 3 |
| 700 | 1 | _ | |a Constantinescu, Andrei-Emil |b 4 |
| 700 | 1 | _ | |a Borges, Carolina |b 5 |
| 700 | 1 | _ | |a Legge, Danny |0 0000-0002-3897-5861 |b 6 |
| 700 | 1 | _ | |a Burrows, Kimberley |b 7 |
| 700 | 1 | _ | |a Huyghe, Jeroen R |0 0000-0001-6027-9806 |b 8 |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 9 |u dkfz |
| 700 | 1 | _ | |a Castellvi-Bel, Sergi |b 10 |
| 700 | 1 | _ | |a Chan, Andrew T |b 11 |
| 700 | 1 | _ | |a Kweon, Sun-Seog |b 12 |
| 700 | 1 | _ | |a Le Marchand, Loic |b 13 |
| 700 | 1 | _ | |a Li, Li |b 14 |
| 700 | 1 | _ | |a Cheng, Iona |b 15 |
| 700 | 1 | _ | |a Pai, Rish K |b 16 |
| 700 | 1 | _ | |a Figueiredo, Jane C |b 17 |
| 700 | 1 | _ | |a Murphy, Neil |b 18 |
| 700 | 1 | _ | |a Gunter, Marc J |b 19 |
| 700 | 1 | _ | |a Timpson, Nicholas J |b 20 |
| 700 | 1 | _ | |a Vincent, Emma E |0 0000-0002-8917-7384 |b 21 |
| 773 | _ | _ | |a 10.7554/eLife.87894 |g Vol. 12, p. RP87894 |0 PERI:(DE-600)2687154-3 |p RP87894 |t eLife |v 12 |y 2023 |x 2050-084X |
| 909 | C | O | |o oai:inrepo02.dkfz.de:286383 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b ELIFE : 2022 |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-09-23T12:20:44Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-09-23T12:20:44Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2022-09-23T12:20:44Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-22 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-22 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-22 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b ELIFE : 2022 |d 2023-08-22 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2023-08-22 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2023-08-22 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)C120-20160331 |k C120 |l Präventive Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)C120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|